An open-label, randomized, Phase III Study of Nivolumab in Combination
   with Ipilimumab or with Standard Chemotherapy versus Standard
   Chemotherapy in Patients with previously untreated inoperable or
   metastatic Urothelial Carcinoma (CheckMate-901) - AB 59/17 of the AUO
   First-line Therapy for untreated, non-resectable or metastatic
   Urothelial Carcinoma

Titel:: An open-label, randomized, Phase III Study of Nivolumab in Combination with Ipilimumab or with Standard Chemotherapy versus Standard Chemotherapy in Patients with previously untreated inoperable or metastatic Urothelial Carcinoma (CheckMate-901) - AB 59/17 of the AUO First-line Therapy for untreated, non-resectable or metastatic Urothelial Carcinoma
Dokumenttyp:: Editorial Material
Autor(en):: Rexer, H.; Retz, M.; Waller, C.
Zeitschriftentitel:: Urologe A
Jahr:: 2018
Band / Volume:: 57
Heft / Issue:: 7
Seitenangaben Beitrag:: 880-881
Volltext / DOI:: doi:10.1007/s00120-018-0698-z
Print-ISSN:: 0340-2592
TUM Einrichtung:: Urologische Klinik und Poliklinik
BibTeX

Vorkommen: